Literature DB >> 34670191

Optimization of Ex Vivo Machine Perfusion and Transplantation of Vascularized Composite Allografts.

Laura C Burlage1, Alexandre G Lellouch2, Corentin B Taveau3, Philipp Tratnig-Frankl3, Casie A Pendexter4, Mark A Randolph3, Robert J Porte5, Laurent A Lantieri6, Shannon N Tessier4, Curtis L Cetrulo3, Korkut Uygun4.   

Abstract

BACKGROUND: Machine perfusion is gaining interest as an efficient method of tissue preservation of Vascularized Composite Allografts (VCA). The aim of this study was to develop a protocol for ex vivo subnormothermic oxygenated machine perfusion (SNMP) on rodent hindlimbs and to validate our protocol in a heterotopic hindlimb transplant model.
METHODS: In this optimization study we compared three different solutions during 6 h of SNMP (n = 4 per group). Ten control limbs were stored in a preservation solution on Static Cold Storage [SCS]). During SNMP we monitored arterial flowrate, lactate levels, and edema. After SNMP, muscle biopsies were taken for histology examination, and energy charge analysis. We validated the best perfusion protocol in a heterotopic limb transplantation model with 30-d follow up (n = 13). As controls, we transplanted untreated limbs (n = 5) and hindlimbs preserved with either 6 or 24 h of SCS (n = 4 and n = 5).
RESULTS: During SNMP, arterial outflow increased, and lactate clearance decreased in all groups. Total edema was significantly lower in the HBOC-201 group compared to the BSA group (P = 0.005), 4.9 (4.3-6.1) versus 48.8 (39.1-53.2) percentage, but not to the BSA + PEG group (P = 0.19). Energy charge levels of SCS controls decreased 4-fold compared to limbs perfused with acellular oxygen carrier HBOC-201, 0.10 (0.07-0.17) versus 0.46 (0.42-0.49) respectively (P = 0.002).
CONCLUSIONS: Six hours ex vivo SNMP of rodent hindlimbs using an acellular oxygen carrier HBOC-201 results in superior tissue preservation compared to conventional SCS.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Energy charge; Face transplantation; Free flap; Limb transplantation; Oxygen carrier; Oxygenated machine perfusion; Plastic surgery; Preservation; Vascularized composite allotransplantation

Mesh:

Substances:

Year:  2021        PMID: 34670191      PMCID: PMC8712379          DOI: 10.1016/j.jss.2021.09.005

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  37 in total

1.  Preservation of amputated extremities by extracorporeal blood perfusion; a feasibility study in a porcine model.

Authors:  Mihai A Constantinescu; Erhard Knall; Xiufang Xu; David M Kiermeir; Hansjörg Jenni; Erich Gygax; Robert Rieben; Andrej Banič; Esther Vögelin
Journal:  J Surg Res       Date:  2010-02-21       Impact factor: 2.192

2.  Subnormothermic machine perfusion for ex vivo preservation and recovery of the human liver for transplantation.

Authors:  B G Bruinsma; H Yeh; S Ozer; P N Martins; A Farmer; W Wu; N Saeidi; S Op den Dries; T A Berendsen; R N Smith; J F Markmann; R J Porte; M L Yarmush; K Uygun; M-L Izamis
Journal:  Am J Transplant       Date:  2014-04-23       Impact factor: 8.086

Review 3.  Immunobiology in VCA.

Authors:  Christina L Kaufman; Michael R Marvin; Paula M Chilton; James B Hoying; Stuart K Williams; Huey Tien; Tuna Ozyurekoglu; Rosemary Ouseph
Journal:  Transpl Int       Date:  2016-03-24       Impact factor: 3.782

4.  Superoxide dismutase mimetic m40401 reduces ischemia-reperfusion injury and graft coronary artery disease in rodent cardiac allografts.

Authors:  Seiichiro Murata; Douglas N Miniati; Murray H Kown; Mark L Koransky; Maarten A Lijkwan; Leora B Balsam; Robert C Robbins
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

5.  Ex Situ Perfusion of Human Limb Allografts for 24 Hours.

Authors:  Nicole L Werner; Fares Alghanem; Stephanie L Rakestraw; Dylan C Sarver; Bruce Nicely; Richard E Pietroski; Paul Lange; Steven M Rudich; Christopher L Mendias; Alvaro Rojas-Pena; John C Magee; Robert H Bartlett; Kagan Ozer
Journal:  Transplantation       Date:  2017-03       Impact factor: 4.939

6.  Infrared fluorescence imaging of lymphatic regeneration in nonhuman primate facial vascularized composite allografts.

Authors:  Gerhard S Mundinger; Mitsunaga Narushima; Helen G Hui-Chou; Luke S Jones; Jinny S Ha; Steven T Shipley; Cinthia B Drachenberg; Amir H Dorafshar; Isao Koshima; Stephen T Bartlett; Rolf N Barth; Eduardo D Rodriguez
Journal:  Ann Plast Surg       Date:  2012-03       Impact factor: 1.539

7.  A Mobile Extracorporeal Extremity Salvage System for Replantation and Transplantation.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Geoffroy Sisk; Harriet Kiwanuka; Ericka M Bueno; Alexander Dermietzel; Muayyad Alhefzi; Mario Aycart; Yannick Diehm; Bohdan Pomahac
Journal:  Ann Plast Surg       Date:  2016-03       Impact factor: 1.539

8.  First human facial retransplantation: 30-month follow-up.

Authors:  Laurent Lantieri; Bernard Cholley; Cedric Lemogne; Romain Guillemain; Nicolas Ortonne; Philippe Grimbert; Eric Thervet; Alexandre G Lellouch
Journal:  Lancet       Date:  2020-11-28       Impact factor: 79.321

9.  Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions.

Authors:  P Fontes; R Lopez; A van der Plaats; Y Vodovotz; M Minervini; V Scott; K Soltys; S Shiva; S Paranjpe; D Sadowsky; D Barclay; R Zamora; D Stolz; A Demetris; G Michalopoulos; J W Marsh
Journal:  Am J Transplant       Date:  2015-02       Impact factor: 8.086

10.  Development of an Extracorporeal Perfusion Device for Small Animal Free Flaps.

Authors:  Andreas M Fichter; Lucas M Ritschl; Anna Borgmann; Martin Humbs; Peter B Luppa; Klaus-Dietrich Wolff; Thomas Mücke
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

View more
  1 in total

Review 1.  Improving the ischemia-reperfusion injury in vascularized composite allotransplantation: Clinical experience and experimental implications.

Authors:  Jiqiang He; Umar Zeb Khan; Liming Qing; Panfeng Wu; Juyu Tang
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.